Outlook Therapeutics, Inc (OTLK)

A. Company Overview

Outlook Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for ophthalmic conditions, particularly utilizing the anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody bevacizumab. The company aims to launch the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications, targeting diseases such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The anticipated direct commercial launch will primarily focus on the United States, followed by potential expansion into markets like the United Kingdom, Europe, Japan, and others, either directly or through strategic partnerships.

Outlook Therapeutics submitted a Biologics License Application (BLA) for its product candidate ONS-5010 (LYTENAVA, bevacizumab-vikg) in March 2022. While the initial BLA was voluntarily withdrawn to address additional information requests from the FDA, a re-submission occurred in August 2022. The FDA accepted this BLA for filing with review expected by August 29, 2023, which resulted in a Complete Response Letter (CRL). The CRL cited concerns regarding chemical, manufacturing and control (CMC) issues and the need for additional clinical trials, particularly an adequately controlled trial with substantial evidence.

B. Business Model and Product Development

The primary focus of Outlook Therapeutics encompasses the development and commercialization of ONS-5010, which is formulated for intravitreal injection. This formulation is intended to address notable gaps in the current treatment landscape, particularly the risks associated with the off-label use of Avastin (the reference product for unapproved use) and its repackaging by compounding pharmacies, which may compromise drug potency, sterility, and safety.

The development journey of ONS-5010 has involved multiple clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE, each designed to evaluate various facets of the drug’s efficacy and safety. NORSE ONE provided proof-of-concept results, while NORSE TWO was a pivotal Phase 3 study that showcased significant efficacy compared to ranibizumab (Lucentis), meeting both primary and key secondary endpoints with clinically relevant outcomes.

As part of ensuring the drug meets regulatory standards, Outlook Therapeutics agreed to conduct an additional clinical trial (NORSE EIGHT) to fulfill FDA requirements following discussions aimed at supporting the BLA resubmission.

C. Market Opportunity

The company operates in the ophthalmological market, particularly focusing on wet AMD, a prevalent cause of vision loss in individuals over 50. With over 2.9 million patients affected by this condition in the United States, Europe, and Japan, the potential market for anti-VEGF therapies is vast. In 2020, the annual revenue for these therapies globally was estimated at $13.1 billion, with significant shares attributed to the United States and Europe.

The lack of approved ophthalmic bevacizumab products provides a unique advantage for Outlook Therapeutics. The current practice often involves the use of repackaged Avastin, which raises concerns related to safety and efficacy. If approved, ONS-5010 is positioned to offer a reliable, compliant alternative that could enhance patient outcomes and overall treatment standards.

D. Competitive Landscape

Outlook Therapeutics faces considerable competition from established pharmaceutical and biotechnology companies. The major competitors in the market include well-known brands offering anti-VEGF therapies such as EYLEA, LUCENTIS, and BEOVU, as well as newer entrants like BYOOVIZ. The competitive environment also includes off-label users of Avastin by compounding pharmacies.

The company’s strategy includes offering ONS-5010 at a cost-effective price point, aiming to be a less expensive alternative to existing expensive branded drugs while providing a safer, more stable solution compared to repackaged Avastin. The familiarity of physicians with off-label Avastin usage is seen as an advantage for ONS-5010 acceptance once it receives approval.

E. Regulatory Landscape

Outlook Therapeutics operates within a complex regulatory environment, primarily governed by the FDA in the United States and the European Medicines Agency (EMA) in Europe. The company has navigated the intricate processes of submitting INDs and BLAs, engaging with regulatory authorities for approvals and compliance.

The expected 12 years of regulatory exclusivity for ONS-5010 in the U.S. and potential 10 years in Europe, if approved, would provide a substantial competitive edge, allowing the company to establish a position within a market currently dominated by off-label treatments.

F. Manufacturing and Supply Chain

To ensure the quality of ONS-5010, Outlook Therapeutics partners with contract manufacturers, specifically FujiFilm Diosynth Biotechnologies and Ajinomoto Bio-pharma Services. These collaborations aim to fulfill cGMP (current Good Manufacturing Practices) requirements for product manufacturing. The company has implemented a supply agreement for pre-filled syringes to enhance safety and usability, which addresses common issues associated with traditional syringe malfunction and contamination.

G. Collaboration and Partnership Strategy

Outlook Therapeutics engages in strategic collaborations and licensing agreements to bolster its development and commercialization efforts. Notable partnerships, including a relationship with Cencora for logistics and distribution in the U.S., aim to facilitate the anticipated rollout of ONS-5010. Internationally, outlook towards partnering or collaboration remains central as the company seeks to penetrate global markets.

Moreover, the company has established joint ventures for the licensing of its product candidates in certain territories, promoting broader access to its therapies in diverse markets. These strategic moves are directed toward maximizing product exposure and leveraging shared resources to enhance developmental pathways.

H. Intellectual Property

The company’s success relies, in part, on its capacity to secure and maintain its proprietary technologies. This includes multiple patents related to formulations and manufacturing processes. By establishing defensive strategies and engaging in continual monitoring of intellectual property rights, Outlook Therapeutics aims to protect its innovations and maintain competitiveness within the biopharmaceutical sector.